United Therapeutics (UTHR) Getting Somewhat Favorable Media Coverage, Study Shows
Media coverage about United Therapeutics (NASDAQ:UTHR) has been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.7992605346933 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Christopher Causey Sells 810 Shares of United Therapeutics Co. (UTHR) Stock (americanbankingnews.com)
- RANKED: Best Places To Work – Extra-Large Companies (finance.yahoo.com)
- Liquida Gets Passed Over On Inhaled Treprostonil (seekingalpha.com)
- Biotech Analysis Central Pharma News: MannKind’s Agreement, Advaxis’ Partnership, Sanofi’s FDA Approval (seekingalpha.com)
- MNKD Takes Giant Leap, REPH On Watch, ALRN To Report Study Data In Q4 (markets.businessinsider.com)
Several research firms have issued reports on UTHR. HC Wainwright reiterated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, August 2nd. BidaskClub cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. TheStreet cut shares of United Therapeutics from a “b” rating to a “c+” rating in a research report on Thursday. Credit Suisse Group cut shares of United Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Wednesday, August 8th. Finally, Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price objective on the stock in a research report on Saturday, July 7th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $138.86.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $1.41. The firm had revenue of $444.50 million for the quarter, compared to analysts’ expectations of $368.63 million. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company posted $4.37 EPS. equities analysts forecast that United Therapeutics will post 14.77 earnings per share for the current year.
In related news, Director Judy D. Olian sold 600 shares of the stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $112.38, for a total transaction of $67,428.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Raymond Dwek sold 3,240 shares of the stock in a transaction on Friday, June 29th. The shares were sold at an average price of $113.07, for a total transaction of $366,346.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,890 shares of company stock worth $948,546. Corporate insiders own 8.20% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Article: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.